Skip to main content

Table 2 Objective Response

From: Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: a randomized pilot trial

Objective response (n, %)

Everolimus plus letrozole (n = 20)

FEC (n = 20)

Complete response

0 (0.0)

0 (0.0)

Partial response

13 (65.0)

8 (40.0)

Stable disease

6 (30.0)

10 (50.0)

Progressive disease

1 (5.0)

2 (10.0)

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us